ALLAKOS INC. - COMMON STOCK

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

06 Mar 2023 13:02:00 By Nasdaq GlobeNewswire

Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

29 Nov 2022 04:02:00 By Nasdaq GlobeNewswire

Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

10 Nov 2022 06:02:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

07 Nov 2022 13:05:00 By Nasdaq GlobeNewswire

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

19 Sep 2022 04:00:00 By Nasdaq GlobeNewswire

Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

12 Sep 2022 04:02:00 By Nasdaq GlobeNewswire

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

09 Sep 2022 04:00:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

04 Aug 2022 13:04:00 By Nasdaq GlobeNewswire

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

25 Jul 2022 13:05:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports First Quarter 2022 Financial Results

06 May 2022 13:05:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

01 Mar 2022 13:05:01 By Nasdaq GlobeNewswire

Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

21 Dec 2021 16:14:59 By Nasdaq GlobeNewswire

Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

30 Nov 2021 04:00:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results

08 Nov 2021 13:05:01 By Nasdaq GlobeNewswire

Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation

25 Oct 2021 05:00:01 By Nasdaq GlobeNewswire

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting

24 Oct 2021 12:35:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results

09 Aug 2021 13:01:00 By Nasdaq GlobeNewswire

Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)

07 Jun 2021 05:00:00 By Nasdaq GlobeNewswire

New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms

24 May 2021 04:00:00 By Nasdaq GlobeNewswire

Allakos Reports First Quarter 2021 Financial Results and Provides Business Update

10 May 2021 13:01:00 By Nasdaq GlobeNewswire